{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:25:22Z","timestamp":1791080722776,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004523.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T00:00:00Z","timestamp":1201046400000}}],"reference-count":71,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004523.pub3","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T02:12:31Z","timestamp":1202263951000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women"],"prefix":"10.1002","author":[{"given":"George A","family":"Wells","sequence":"first","affiliation":[{"name":"University of Ottawa Heart Institute; Cardiovascular Research Reference Centre; Room H1-1 40 Ruskin Street Ottawa Ontario Canada K1Y 4W7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Cranney","sequence":"additional","affiliation":[{"name":"Ottawa Hospital; Division of Rheumatology; 1053 Carling Ave Ottawa Ontario Canada K1Y 4E9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Ottawa Civic Hospital \/ Loeb Research Institute; Clinical Epidemiology Unit; 1053 Carling Avenue Ottawa Ontario Canada K1Y 4E9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boucher","sequence":"additional","affiliation":[{"name":"HTA Development Canadian Agency for Drugs and Technologies in Health (CADTH); 865 Carling Ave Suite 600 Ottawa Ontario Canada K1S 5S8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"University of Ottawa; Institute of Population Health; 1 Stewart St. Room 312 Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Welch","sequence":"additional","affiliation":[{"name":"University of Ottawa; Centre for Global Health, Institute of Population Health; 1 Stewart Street, Room 206 Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Coyle","sequence":"additional","affiliation":[{"name":"Ottawa Health Research Institute; Epidemiology and Community Medicine; 451 Smyth Rd. Ottawa Ontario Canada K1H 8M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Ottawa Hospital; Centre for Global Health, Institute of Population Health, Department of Medicine; 1 Stewart Street Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/PL00004152","article-title":"A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis","volume":"7","author":"Clemmesen","year":"1997","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0002|cit2","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"14","key":"10.1002\/14651858.CD004523.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13697130500118126","article-title":"Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial","volume":"8","author":"Hooper","year":"2005","journal-title":"Climacteric"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.[see comment]","volume":"344","author":"McClung","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub3-BIB0006|cit6","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcified Tissue International"},{"issue":"3","key":"10.1002\/14651858.CD004523.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"Journal of Bone & Mineral Research"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00002512-199813010-00008","article-title":"Risedronate. [Review] [36 refs]","volume":"13","author":"Goa","year":"1998","journal-title":"Drugs & Aging"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub3-BIB0014|cit14","first-page":"S404","article-title":"The effects of risedronate plus estrogen compared with estrogen alone in postmenopausal women","volume":"14","author":"Harris","year":"1999","journal-title":"Journal of Bone & Mineral Research"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0015|cit15","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.[see comment]","volume":"86","author":"Harris","year":"2001","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub3-BIB0016|cit16","first-page":"80","article-title":"Risedronate prevents bone loss in early postmenopausal women [abstract]","author":"Hooper","year":"1999","journal-title":"Calcified Tissue International"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Current Medical Research & Opinion"},{"issue":"3","key":"10.1002\/14651858.CD004523.pub3-BIB0018|cit18","first-page":"299","article-title":"Quality of life in the treatment assessment of postmenopausal osteoporosis. [Chinese]","volume":"30","author":"Hu","year":"2005","journal-title":"Zhong Nan da Xue Xue Bao Yi Xue Ban = Journal of Central South University Medical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00774-004-0509-z","article-title":"A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial","volume":"22","author":"Kushida","year":"2004","journal-title":"Journal of Bone & Mineral Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bone.2004.10.014","article-title":"The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study","volume":"36","author":"Leung","year":"2005","journal-title":"Bone"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0021|cit21","first-page":"527","article-title":"Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis","volume":"Medical Science","author":"Li","year":"2005","journal-title":"Journal of Huazhong University of Science and Technology"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub3-BIB0022|cit22","first-page":"17","article-title":"Bisphosphonate therapy.[see comment]. [Review]","volume":"313","author":"Licata","year":"1997","journal-title":"American Journal of the Medical Sciences"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004523.pub3-BIB0023|cit23","first-page":"111","article-title":"Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass","volume":"8","author":"McClung","year":"1998","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0024|cit24","first-page":"S287","article-title":"Risedronate reduces hip fractures in patients with low femoral neck bone mineral density [abstract]","volume":"42","author":"Miller","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub3-BIB0025|cit25","first-page":"121","article-title":"Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women.[see comment]","volume":"19","author":"Reginster","year":"2001","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"49","key":"10.1002\/14651858.CD004523.pub3-BIB0026|cit26","first-page":"34967","article-title":"Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase","volume":"274","author":"Reszka","year":"1999","journal-title":"Journal of Bone and Joint Surgery"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0027|cit27","first-page":"S163","article-title":"Risedronate increases bone mineral density and is well tolerated in postmenopausal women with low bone mineral density","volume":"14","author":"Ribot","year":"1999","journal-title":"Journal of Bone & Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","article-title":"Efficacy of risedronate on clinical vertebral fractures within six months","volume":"20","author":"Roux","year":"2004","journal-title":"Current Medical Research & Opinion"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0029|cit29","first-page":"259","article-title":"Bisphosphonates in the treatment of disorders of mineral metabolism","volume":"6","author":"Singer","year":"1995","journal-title":"Advances in Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcified Tissue International"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub3-BIB0032|cit32","first-page":"419","article-title":"Treatment of osteoporosis with bisphosphonates. [Review]","volume":"27","author":"Watts","year":"1998","journal-title":"Rheumatic Diseases Clinics of North America"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub3-BIB0033|cit33","first-page":"S136","article-title":"Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis","volume":"14","author":"Watts","year":"1999","journal-title":"Journal of Bone & Mineral Research"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","article-title":"Risedronate prevents new vertebral fractures in postmenopausal women at high risk.[see comment]","volume":"88","author":"Watts","year":"2003","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"3-4","key":"10.1002\/14651858.CD004523.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/BMR-2005-183-405","article-title":"Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis","volume":"18","author":"Yildirim","year":"2005","journal-title":"Journal of Back & Musculoskeletal Rehabilitation"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S8756-3282(00)00410-5","article-title":"Effect of high doses of oral risedronate (20 mg\/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis","volume":"28","author":"Zegels","year":"2001","journal-title":"Bone"},{"issue":"11","key":"10.1002\/14651858.CD004523.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD004523.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s001980170072","article-title":"An assessment tool for predicting fracture risk in postmenopausal women","volume":"12","author":"Black","year":"2001","journal-title":"Osteoporos International"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD004523.pub3-BIB0039|cit39","first-page":"S1","article-title":"2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"CMAJ"},{"issue":"14","key":"10.1002\/14651858.CD004523.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1996.00440130053006","article-title":"Mortality following fractures in older women. The study of osteoporotic fractures","volume":"156","author":"Browner","year":"1996","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0041|cit41","unstructured":"Coyle D Hadj Tahar A Murphy G Perras C Skidmore B Boucher M Teriparatide and Bisphosphonates of Treatment of Osteoporosis In Women: A Clinical and Economic analysis Canadian Agency for Drugs and Technologies in Health 2006"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0042|cit42","unstructured":"Cates C Visual Rx NNT Calculator 2.0 http:\/\/www.nntonline.net\/ 2004"},{"issue":"7","key":"10.1002\/14651858.CD004523.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1002\/14651858.CD004523.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","article-title":"Population-based study of survival after osteoporotic fractures","volume":"137","author":"Cooper","year":"1993","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub3-BIB0046|cit46","article-title":"Risedronate for the prevention and treatment of postmenopausal osteoporosis","author":"Cranney","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD004523.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","article-title":"Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women","volume":"149","author":"Cummings","year":"1989","journal-title":"Arch Intern Med"},{"issue":"6964","key":"10.1002\/14651858.CD004523.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women","volume":"12","author":"Doherty","year":"2001","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7010","article-title":"How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study","volume":"7","author":"Egger","year":"2003","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis","volume":"2","author":"Fleiss","year":"1993","journal-title":"Stat Methods Med Res"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0052|cit52","first-page":"1490","article-title":"Grading quality of evidence and strength of recommendations.","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ Jun 19;(7454):1490"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0053|cit53","first-page":"637","article-title":"Osteoporosis","volume-title":"Therapeutic Choices","author":"Hanley","year":"2003"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0054|cit54","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0055|cit55","article-title":"Canadian Adverse drug Reaction Monitoring Program. Risedronate","volume-title":"Adverse reaction database","author":"Health Canada","year":"2005"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0056|cit56","unstructured":"Health Canada Medeffect [website] Health Canada YR:2005"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0057|cit57","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd"},{"issue":"11","key":"10.1002\/14651858.CD004523.pub3-BIB0058|cit58","first-page":"1426","article-title":"Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date","volume":"166","author":"Hodsman","year":"2002","journal-title":"CMAJ"},{"issue":"8","key":"10.1002\/14651858.CD004523.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"Journal of Bone and Mineral Research"},{"issue":"11","key":"10.1002\/14651858.CD004523.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00002018-200225110-00003","article-title":"Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review","volume":"25","author":"Kherani","year":"2002","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"Journal of Bone and Minereral Research"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"Journal of Oral Maxillofacial Surgery"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0063|cit63","first-page":"1233","article-title":"Alendronate and vertebral fracture risk [multiple letters]","volume":"80","year":"2005","journal-title":"Mayo Clinic Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/oxfordjournals.aje.a115204","article-title":"Epidemiology of vertebral fractures in women","volume":"129","author":"Melton","year":"1989","journal-title":"American Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"Diagnosis","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD004523.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0895-4356(03)00110-0","article-title":"Should meta-analysts search Embase in addition to Medline?","volume":"56","author":"Sampson","year":"2003","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0067|cit67","volume-title":"Treating osteoporosis with teriparatide: many unknowns? [Issues in emerging health technologies issue 51]","author":"Shukla","year":"2003"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0068|cit68","volume-title":"Evidence-based Rheumatology","author":"Tugwell","year":"2004"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0069|cit69","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group","volume":"843","author":"WHO","year":"1994","journal-title":"World Health Organ Technical Report Series"},{"issue":"10","key":"10.1002\/14651858.CD004523.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004523.pub3-BIB0071|cit71","unstructured":"Wells GA Cranney A Bouchere M Peterson J Shea B Robinson V Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no 69] Ottawa: Canadian Agency for Drugs and Technologies in Health 2006"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004523.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004523.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:32:10Z","timestamp":1630668730000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004523.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":71,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004523.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD004523.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}